Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

By R. Schiffmann, J. Kopp, H. Austin, S. Sabnis, D. Moore, T. Weibel, J. Balow, R. Brady. Journal of the American Medical Association (JAMA), 2001

1,282 citations recorded by the source corpus.

Subfields: Cancer Research, Physiology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/5f5ee98e272a15f7ac2c3343e1a27444c4da5a7d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. D. Germain

Citations in the corpus

• ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, neutral): “Improvements of cardiac hypertrophy and conduction abnormalities have been obtained with enzyme replacement therapy.(526)”
• Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy (2003, methodology): “However, in contrast to the clinical experience with protein replacement therapy in hemophilia (51, 52), there is no evidence that antibody formation alters efficacy (12, 13).”